340570 - T & L Co., Ltd.

340570 Summary

Medical Devices

Stock Price & Overview

₩29,650 +350 (+1.19%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩29,650 ≈ US$21 · Market cap ₩0.5tn (≈ $340m)

340570 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Revenue	164.2	174.9	115.5	81.6	71.9	40.6	32.6	26.3
Cost of Revenue	91.8	99.4	70.3	47.4	41.4	24.8	19.5	15.6
Gross Profit	72.4	75.5	45.2	34.2	30.5	15.8	13.1	10.7
Selling, General & Administrative	26.0	18.5	14.3	9.9	8.2	6.2	5.4	5.4
Operating Income	46.4	57.0	30.8	24.3	22.3	9.6	7.7	5.3
Finance Income	2.6	3.3	1.9	1.0	0.4	0.1	0.0	0.0
Finance Costs	0.2	0.0	0.4	0.0	0.0	0.0	0.1	0.1
Pretax Income	47.8	62.3	33.1	25.6	23.4	11.5	8.4	5.1
Income Tax Expense	9.7	15.9	5.6	4.4	3.8	1.4	1.1	0.5
Net Income	38.1	46.4	27.4	21.1	19.6	10.0	7.3	4.7
Total Comprehensive Income	38.4	46.3	27.1	21.1	19.8	10.1	7.0	4.4

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Assets	217.1	197.1	142.1	117.0	98.3	79.5	43.3	36.5
Current Assets	126.1	114.3	72.0	58.8	52.4	47.6	15.0	11.3
Cash & Cash Equivalents	73.7	60.7	19.3	20.6	16.6	14.6	4.9	2.8
Inventories	16.3	19.7	12.9	10.6	7.0	5.2	3.6	3.4
Trade Receivables	16.7	16.3	9.9	13.3	8.1	7.1	6.0	4.6
Non-current Assets	91.0	82.8	70.1	58.2	45.9	31.9	28.4	25.3
Property, Plant & Equipment	84.5	74.9	62.7	56.4	42.7	28.6	26.8	23.7
Intangible Assets	3.7	3.6	3.1	1.7	1.7	1.4	1.0	1.2
Total Liabilities	15.9	25.6	12.6	10.9	8.2	7.5	10.1	9.3
Current Liabilities	15.2	23.7	11.3	9.7	7.0	6.3	5.5	4.5
Non-current Liabilities	0.7	2.0	1.3	1.2	1.2	1.2	4.6	4.8
Total Equity	201.2	171.4	129.6	106.1	90.1	72.0	33.2	27.2
Share Capital	4.5	4.5	4.5	4.5	4.5	2.4	2.0	2.0
Retained Earnings	184.9	140.3	98.7	75.3	57.3	39.4	30.6	24.6

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Cash from Operating Activities	37.7	46.6	32.6	15.4	19.0	9.3	7.8	6.4
Cash from Investing Activities	-15.7	-0.7	-30.1	-6.0	-15.3	-24.7	-3.8	-2.9
Purchase of Property, Plant & Equipment	17.6	15.8	13.5	16.0	15.6	3.0	3.9	2.6
Cash from Financing Activities	-8.9	-4.6	-3.7	-5.1	-1.8	25.3	-1.9	-2.6
Dividends Paid	6.1	4.4	3.6	3.3	1.6	1.3	1.0	1.0
Net Change in Cash	13.1	41.3	-1.2	4.0	2.0	9.7	2.1	0.8

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	56.0	45.1	33.4	40.7	38.8	51.3	46.5	48.7	54.8	24.8
Cost of Revenue	26.1	22.5	20.7	22.0	22.9	26.1	27.7	26.8	30.5	14.5
Gross Profit	29.9	22.6	12.7	18.7	15.9	25.2	18.8	22.0	24.4	10.4
Selling, General & Administrative	5.0	4.3	8.6	6.5	5.9	5.0	7.7	4.1	3.6	3.1
Operating Income	25.0	18.3	4.0	12.1	10.0	20.2	11.2	17.8	20.7	7.2
Finance Income	0.6	0.5	0.8	0.8	0.5	0.5	1.6	0.5	0.5	0.7
Finance Costs	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	-0.0	0.0
Pretax Income	26.5	20.7	3.7	14.3	8.6	21.3	15.2	16.5	22.0	8.6
Income Tax Expense	6.6	4.2	0.7	2.9	0.7	5.4	6.4	3.3	4.7	1.5
Net Income	19.9	16.4	3.1	11.3	7.8	15.9	8.7	13.2	17.3	7.1
Total Comprehensive Income	20.1	16.6	3.6	11.4	7.6	15.8	8.6	13.2	17.4	7.2

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	253.2	239.6	217.1	219.2	208.5	212.0	197.1	184.4	171.1	153.4
Current Assets	160.7	147.5	126.1	130.3	121.8	128.0	114.3	104.8	96.6	82.3
Cash & Cash Equivalents	36.5	40.3	73.7	16.1	54.4	54.8	60.7	16.8	15.0	9.2
Inventories	22.9	16.5	16.3	17.3	17.8	18.6	19.7	17.5	16.9	19.1
Trade Receivables	—	—	16.7	20.0	16.5	24.7	16.3	17.0	25.6	14.0
Non-current Assets	92.5	92.1	91.0	88.9	86.7	84.1	82.8	79.5	74.5	71.1
Property, Plant & Equipment	—	86.0	84.5	82.9	80.5	76.2	74.9	71.6	67.1	63.8
Intangible Assets	3.9	3.8	3.7	3.8	3.8	3.6	3.6	3.7	3.2	3.1
Total Liabilities	29.0	33.9	15.9	20.1	19.7	30.8	25.6	21.5	21.4	21.1
Current Liabilities	28.2	33.3	15.2	17.0	17.4	28.5	23.7	19.1	19.4	19.5
Non-current Liabilities	0.8	0.5	0.7	3.0	2.3	2.3	2.0	2.4	2.0	1.7
Total Equity	224.2	205.8	201.2	199.1	188.8	181.2	171.4	162.9	149.7	132.3
Share Capital	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5
Retained Earnings	209.2	189.2	184.9	169.2	157.9	150.0	140.3	131.9	118.7	101.4

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	21.5	8.8	6.3	9.7	13.9	7.8	10.9	23.7	11.4	0.6
Cash from Investing Activities	-13.4	-42.5	53.0	-46.9	-8.1	-13.8	32.9	-21.8	-1.1	-10.7
Purchase of Property, Plant & Equipment	4.8	2.5	4.0	3.7	7.7	2.2	4.7	5.9	3.4	1.8
Cash from Financing Activities	-11.8	-0.0	-1.6	-1.2	-6.1	-0.0	-0.0	-0.0	-4.5	-0.0
Dividends Paid	—	—	0.0	0.0	6.1	0.0	0.0	0.0	4.4	0.0
Net Change in Cash	-3.7	-33.4	57.8	-38.3	-0.4	-5.9	43.9	1.8	5.8	-10.1

Consolidated (CFS), from DART. 8 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

340570 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	164.2	-6.1%	+26.2%	+32.2%	—
Operating income	46.4	-18.6%	+24.0%	+37.0%	—
Net income	38.1	-18.0%	+21.7%	+30.5%	—
EPS	₩2,369	-18.0%	+21.7%	+30.5%	—
Operating cash flow	37.7	-19.1%	+34.7%	+32.2%	—
Shareholders' equity	201.2	+17.3%	+23.8%	+22.8%	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

340570 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	44.1%	43.2%	39.1%	41.9%	42.4%	38.9%
Operating margin	28.2%	32.6%	26.7%	29.8%	31.1%	23.6%
Net margin	23.2%	26.5%	23.8%	25.9%	27.2%	24.7%
Return on equity	20.4%	30.8%	23.3%	21.5%	24.2%	19.1%
Return on assets	18.4%	27.4%	21.2%	19.6%	22.0%	16.4%
Operating cash flow / revenue	23.0%	26.6%	28.2%	18.9%	26.4%	23.0%
Capex / revenue	10.7%	9.1%	11.7%	19.6%	21.7%	7.3%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 340570

Symbol	Last Price
096530Seegene, Inc.	₩31,900 +1.1%
491000Livs Med, Inc.	₩34,500 +3.6%
041830In Body Co., Ltd.	₩61,100 +2.5%
445680Curiox Biosystems Co., Ltd.	₩47,650 -1.5%
458870Seers Co., Ltd.	₩21,350 +3.1%
137310SD Biosensor	₩6,160 -0.3%
377740Bio Note, Inc.	₩4,790 -0.2%
099190i-SENS, Inc.	₩16,470 +0.0%
336570WON Tech Co., Ltd.	₩4,905 +0.9%
174900Ab Clon, Inc.	₩21,600 +5.9%

Compare all 13 in Medical Devices

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.